

	Please state all personal interests that you may have in any company which might be perceived to have a conflict of interest with UK Primary Immunodeficiency Network; this includes shares, share options etc	Please list here any honoraria for advisory groups or consultative duties paid to you by any company or group which might be perceived to have a conflict of interest with UK Primary Immunodeficiency Network. Please also include any grants made to allow attendance at educational meetings whether this was for registration, accommodation or travel expenses. The precise details and amount of honoraria etc. do not need to be stated but each event should be noted	Please state here the connections which exist between the department in which you work and pharmaceutical companies. This includes investigator led studies, studies led by the pharmaceutical company and other grants and awards. Please also state connections which exist between the department in which you work and any other company which might be perceived to lead to a conflict of interest with UK Primary Immunodeficiency Network
Peter Arkwright	None	CSL Behring conference attendance	None
Claire Bethune	No financial interests I am a member of the crg for immunology and Allergy I am clinical lead for QPIDS accreditation scheme	In the last 12 months I have had travel expenses to attend a meeting sponsored by ALK	I have been PI for the following pharma sponsored trials: Octapharma, Shire and Grifols.
Matthew Buckland	None	Consultancy for Octapharma	Studies with Shire, Octapharma, CSL Behring, Biotest
Suzy Elcombe	None	None	None
Bill Egner	None	None in recent memory. I gave a talk at a Phadia meeting but declined the honorarium as they would not pay it to the general departmental travel fund instead	None
Tomaz Garcez	None	Attendance at EAACI 2015 supported by CSL Behring Attendance at UKPIN 2015 supported by UKPIN Attendance at EAACI 2016 supported by Shire Honoraria from Shire for advisory board and chairing UK Immunology Forum (both March 2017) Attendance at UK Immunology Forum supported by Shire Honoraria from CSL Behring for advisory board (May 2017 - pending) Attendance at 10th C1 Inhibitor Deficiency Workshop 2017 supported by CSL Behring (pending) Attendance at EAACI 2017 supported by Shire (pending)	Investigator on iOS Study (Shire) Investigator on OPuS-2 Study (BioCryst) Investigator on Prion study (NHS funding) Investigator for UK anaphylaxis death register Department hosts the research co-ordinator for the UKPID Registry (UKPIN)
Kimberly Gilmour	None	Centre for Chronic Immunodeficiency, Freiberg, to teach on CID summer school (travel and accommodation costs) – June 2017	Orchard is sponsoring the ADA gene therapy trial for which we both issue products and monitor patients Genethon is sponsoring the CGD and WAS gene therapy trials for which we both issue products and monitor patients Servier sponsoring the UCART trial for which our lab is contracted to undertake monitoring
Richard Herriot	Shareholder, Time for Medicine Limited.	CSL Behring UK Ltd. – support for attendance at, and contribution to, meeting on therapeutic uses of normal human immunoglobulin, Mexico City, 22-23/2/17. Professional fee (£1500) + business class travel + accommodation. No registration fee	No relevant interests

Rashmi Jain	None	I have received grants to allow attendance at educational meetings for instance ESID, UKPIN, BSACI, Immunology forum. I was on the advisory board for Shire/Baxalta for Immunoglobulins	I participated in OPuS 2 and APex clinical trial by BioCryst, and in GAN06 trial by Octapharma
Stephen Jolles	UKPIN Steering Committee ESID Clinical Working Group – Secretary EAACI Immunology Working Group Board Member Immunology Training Program Director – Wales Department of Health – Commercial Medicines Unit Association of Clinical Pathologists – Immunology Committee Member Immune Deficiency Patients Group Wales – Medical Advisor Frontiers in Immunology – Editorial Board Clinical and Experimental Immunology – Editorial Board Journal of Clinical Immunology – Editorial Board Current Opinion in Allergy and Clinical Immunology – Co-Editor Immunology Section Journal of Clinical Pathology – Immunology Editor	Uptodate – Author Drug Safety Committee – Biotest Drug Safety Committee (3) – UCB Pharma Advisory Board, Conference, Speaker – CSL Behring, Shire, UCB Pharma, Octapharma, Biotest, BPL, LFB, Grifols, SOBI	BIPAD Study Grant FitPAD Study Grant SIGNET Study Grant BPL – Clinical Trial Octapharma – Clinical Trial Shire – Clinical Trial Grifols – Clinical Trial Mepolizumab - Clinical Trial Biocryst – Clinical Trial
Sara Marshall *2016 response*	<i>I am a full time employee of the Wellcome Trust, a global charitable organisation dedicated to improving health</i>	None	None
Ravishankar Sargur	Allergy & Immunology Clinics Limited	CSL Behring – C1 Inhibitor workshop (2017) Shire (ESID 2016) Honoraria for Market Research for Immunoglobulin & HAE products	None
Gavin Spickett	None	None	Colleague involved in Shire's iOS study
Christine Symons	I have no personal interests	Over the last 20 years I have been supported to attend various Conferences and Learning Opportunities (including registration, travel and accommodation), and have received Honoraria for attendance at advisory boards from Grifols, Octapharma, CSL Behring and Shire	Commercial trials have been undertaken in the department in which I work in collaboration with Shire, CSL Behring, Octapharma and Grifols